Cancer chemotherapy

41
CANCER CHEMOTHERAPY Dr.Zulcaif Ahmad Hajvery University

Transcript of Cancer chemotherapy

Page 1: Cancer chemotherapy

CANCER CHEMOTHERAPY Dr.Zulcaif Ahmad

Hajvery University

Page 2: Cancer chemotherapy

Cancer

It is an unwanted and uncontrolled growth of cells.

Hajvery University

Page 3: Cancer chemotherapy

OverviewOut of the total number of people diagnosed

with cancer, less than one fourth can be cured with Radiotherapy and Surgery While

the rest needs chemotherapy. 10% of those treated gets a cure, otherwise it just adds to the better life quality and life span increase upto 5 years (65%). Cancer is

the 2nd highest death causing disease.

Hajvery University

Page 4: Cancer chemotherapy

• PRINCIPLE: Cancer chemotherapy strives to cause a lethal cytotoxic event or apoptosis in the cancer cell that can arrest tumor's progression.

• Indication: Chemotherapy is indicated when neoplasms are disseminated and are not amenable to surgery.

• Goal : Long term disease free survival.

• Tumor Susceptibility: Rapidly proliferating cells are more prone to chemotherapeutic drugs as compared to slow proliferating cells.

Hajvery University

Page 5: Cancer chemotherapy

Types of Chemotherapy•Adjuvant Chemotherapy: Used as a

supplement treatment to attack micrometastases following surgery and radiation treatment.

• •Neo adjuvant Chemotherapy: Given

prior to the surgical procedure in an attempt to shrink the cancer.

•Maintenance Chemotherapy: Given in lower doses to assist in prolonging remission.

Hajvery University

Page 6: Cancer chemotherapy

Cell Cycle

Hajvery University

Page 7: Cancer chemotherapy

CELL CYCLE SPECIFIC DRUGS

CELL CYCLE NON-SPECIFIC…

These are specific to the cells that are traversing the cell cycle and do not act against cells in the non proliferating Go phase.

They target both proliferating (Traversing cell cycle) and non proliferating (in G0 phase) cells without any discrimination.

Hajvery University

Page 8: Cancer chemotherapy

Classification of Chemotherapeutic Drugs

ANTI METABOLITES ANTI BIOTICSAlkylating

AgentsMonoclonal Antibodies

Microtubule Inhibitors

Hajvery University

Page 9: Cancer chemotherapy

1 - ANTIMETABOLITESAntimetabolites are structurally related to compounds already present in our cells and through variable mechanisms interfere with the availability of normal Purine and Pyrimidine nucleotide precursors.Their maximal toxic effects are in S phase of the cell cycle.These are further sub classed as:a) Folate antagonists.b) Purine antagonists.c) Pyrimidine antagonists.

Hajvery University

Page 10: Cancer chemotherapy

(a) METHOTREXATEMOA: •Methotrexate (MTX) is a competitive follic

acid antagonist that binds to the active catalytic site of Dihydrofolate reductase (DHFR) so the reduction of Folic acid to Tetrahydrofolate is interfered.

•Just like Tetrahydrofolate, it becomes polyglutamated in the cell - a process that favour its cellular retention owing to increased negative charge and its polyglutamates also potentially inhibits DHFR.

•Deficiency of this coenzyme in S phase leads to the failure of cell to form Thymidine, adenine, guanine, methionine,serine etc and hence DNA and protein synthesis is depressed that let not cell undergo S phase and the cell dies.

Hajvery University

Page 11: Cancer chemotherapy

Follic Acid

Dihydrofollate Reductase

Tetrahydrofollate

Methotrexate

Thymidine, Adenine, Guanine, Methionine,Serine.

DNA

CELL DIES

Hajvery University

Page 12: Cancer chemotherapy

(b) 6-Mercaptopurine MOA: It is a purine analog. • 6-MP first converts into nucleotide analog form

i.e 6-MP Ribose Phosphate better known as 6-thioinosinnic acid (TIMP).• TIMP then inhibits the first step of Purine ring

biosynthesis and also blocks the formation of AMP and Xanthinuric acid from inosinic acid.• TIMP also converts into thioguanine

monophosphate (TGMP) which after phosphorylation to di and triphosphates can be incorporated into RNA

Hajvery University

Page 13: Cancer chemotherapy

• It also forms deoxy-ribonucleotides that are incorporated in DNA.

As a result, non functional DNA and RNA are formed.

Hajvery University

Page 14: Cancer chemotherapy

Hajvery University

6-MPHGPRT

TIMP

Deoxyribonucleotidesthioguanine mono/di/tri phosphate

inosinic acid AMP and Xanthinuric acid

NON FUNCTIONAL DNANON FUNCTIONAL RNA

Page 15: Cancer chemotherapy

(c) 5- FluorouracilMOA:

5-Fu is a pro drug and after activation it forms Ribosyl and Deoxyribosyl metabolites which perform following functions:1. 5-Fluoro-2-deoxyuridine-5’-mono phosphate

(FdUMP) : Forms covalently bound ternary complex with the enzyme Thymidyle Synthase and reduced Folate thus inhibiting Thymidylate synthesis which leads to inhibition of DNA due to lack of Thymine – “Thymine less Death.”

Hajvery University

Page 16: Cancer chemotherapy

2. 5-Fluorouridine-5’-triphosphate (FUTP) : It is incorporated into the RNA and interferes with RNA processing e.g mRNA translation.3. 5-fluorodeoxyuridine-5’-triphosphate : It is incorporated into cellular DNA resulting in inhibition of cellular DNA function and synthesis.

Hajvery University

Page 17: Cancer chemotherapy

Hajvery University

5- Fluorouracil

ACTIVATION

5-Fluoro-2-deoxyuridine-5’-mono phosphate (FdUMP)

5-fluorodeoxyuridine-5’-triphosphate

5-Fluorouridine-5’-triphosphate (FUTP)

NON FUNCTIONAL DNA

NON FUNCTIONAL RNA

Thymine less Death

Page 18: Cancer chemotherapy

2. MONOCLONAL ANTIBODIES

Monoclonal antibodies are produced from cloning of Specific hybrid B-cells which produce antibodies for specific (desired) antigen e.g HER2 or EGFR or VEGF.

Hajvery University

Page 19: Cancer chemotherapy

(a) RituximabMOA: Its antigen is CD-20 site found in normal and malignant B-Cells and plays role in cell cycle initiation and cell differentiation.The Fab domain of the antibody binds with its antigen while Fc segments recruits immune effector functions i.e through complement and antibody mediated cytotoxicity of B-cells.

Hajvery University

Page 20: Cancer chemotherapy

ALKYLATING AGENTS

Hajvery University

Page 21: Cancer chemotherapy

• Cyclophosphamide, Melphalan• Chlorambucil,Mechlorethamine

Nitrogen mustards

• Carmustine , lomustine• semustineNitrosourease

• Triethylenemelamine , • TriethylenethiophospharamideAziridines

• BusulfanAlkylsulfonates

• DecarbazineTriazenes

• Procarbazine , Hexamethylmelamine• Pentamethylmelamine, Csplatin

Miscellaneous alkylating agents Hajvery University

Page 22: Cancer chemotherapy

MECHANISM OF ACTION • Alkylating agents

exert their cytotoxic effects by covalently binding to nucleophilic groups on various cell constiuents. Alkylation of DNA is probably the crucial cytotoxic reaction that is lethal to tumor cell s.

Hajvery University

Page 23: Cancer chemotherapy

Hajvery University

Page 24: Cancer chemotherapy

NITROGEN MUSTURDS MOA(Cyclophosphamide)

• Kill rapidly proliferating cells as well as non-proliferating cells as a result of alkylation of RNA, DNA and essential protiens.• Most favoured sites for alkylation being 7-nitrogen and

6-oxygen of guanine.• Cross linking, resulting in inhibition of DNA replication.• Mispairing of bases = production of defective protiens• Depurination of DNA = strand break• ADR’s :-• Nausea, Vomitting , Moderate depression of

peripheral blood cell count.Hajvery University

Page 25: Cancer chemotherapy

Nitrosoureas (Penetrate CNS)MOA:They exerts cytotoxic effects by an alkylation that inhibit

replication and, eventually, RNA and protien synthesis. Although they alkylate DNA in resting cells, cytotoxicity is expressed priemerly on cells that are actively dividing.

Also inhibit several key enzymatic processes by carbamoylation of aminoacids in protiens in the targeted cells.

ADR’s:- Renal toxicity, pulmonary fibrosis, delayed hematopoietic

depressionHajvery University

Page 26: Cancer chemotherapy

Hajvery University

Cyclophosphamide

DNA

RNA

PROTEINS

ALKYLATION

CELL DEATH

Page 27: Cancer chemotherapy

Antibiotics• Dactinomycin• Daunorubicin• Bleomycinn• Doxorubicin• Epirubicin• Idarubicin

Hajvery University

Page 28: Cancer chemotherapy

Dactinomycin•MOA:• The drug intercalates into the minor groove of the double

helix between guanine-cytosine base pair of DNA forming a stable dactinomysin-DNA complex. The complex interfare primarily with DNA dependent RNA polymerase, although at high doses, dactinomycin hinders DNA synthesis. The drug also causes single-strand breaks, possibly due to action on topoisomerase II or by generation of free radicals.• Resistance:• Resistance is due to an increased efflux of the antibiotic

from the cell via p-glycoprotien.DNA repair may also play a role. Hajvery University

Page 29: Cancer chemotherapy

ADR’s• Bone marroe depression • Nausea• Vomitting• Diarrhea• Alopecia

Hajvery University

Page 30: Cancer chemotherapy

Bleomycin •MOA: • DNA strand scission and direct oxidation of purine or

pyrimidine bases.• DNA-bleomycin-Fe+2 complex appears to undergo

oxidation to bleomycin-Fe+3. The liberated electrons react with oxygen to form superoxide or hydroxyl radicals, which, in turn, attack the phosphodiester bonds of DNA, Resulting in strand-breakage and chromosomal aberrations.• ADR’s:• Pulmonary toxicity• Cough• Hypertrophic skin changes

Hajvery University

Page 31: Cancer chemotherapy

Hajvery University

DNA-bleomycin-Fe+2 complex

bleomycin-Fe+3

superoxide or hydroxyl radicals

phosphodiester bonds of DNA

DNA Lysis

BLEOMYCINE

CONVERSI

ONCONVERSION

Electrons

Page 32: Cancer chemotherapy

Hajvery University

Page 33: Cancer chemotherapy

3. MICROTUBULE INHIBITORS

Microtubule inhibitors are cell cycle and phase specific drugs that disturb the partitioning equilibrium of DNA into two new daughter cells through disrupting mitotic spindle in the M phase of the cell cycle.

Hajvery University

Page 34: Cancer chemotherapy

VINCRISTINE & VINBLASTIN

MOA: Blocks Mitosis in Metaphase.They binds to Tubulin (microtubular protein) through a GTP dependent process thus inhibiting the ability of Tubulin to polymerize to form microtubules. Due to this, paracrystals of Tubulin dimers and the drug are aggregated within the cell and the dysfunctional spindle apparatus freezes in Metaphase and chromosomal segregation and cell proliferation is inhibited.

Hajvery University

Page 35: Cancer chemotherapy

Hajvery University

Tubulin Microtubules

Polymerization

Mitotic Spindle Apparatus

Chromosomal Segregation

VINCRISTINE

Page 36: Cancer chemotherapy

STEROID HORMONES AND THEIR ANTAGONISTS

Tumors that are hormone sensitive may be either:1- In which tumor regresses following treatment with a specific hormone. (Hormone Sensitive)2- In which removal of a specific hormone triggers regression. (Hormone Responsive)3- Both.

Hajvery University

Page 37: Cancer chemotherapy

Hormone Responsive therapy is more palliative and Drugs like Prendisone and Tamoxifin are used that exert their effects by competing intracellular hormones for their receptor binding and resulting in affected gene expression.

Hajvery University

Page 38: Cancer chemotherapy

Other Drugs• Asparginase.• Carboplatin.• Cisplatin.• Etoposide.• Interferones.• Imatinib.• Protecan

Hajvery University

Page 39: Cancer chemotherapy

Problems associated with Chemotherapy.

Resistance: Some neoplastic cells are inherently

resistant to most of chemotherapeutic drugs.

Others may Acquire Resistannce:• Specific to a drug: Through change in

mitotic apparatus (Gene amplification)• Multi drug Resistance: Through over

expression of MDR1 and MRP1 Hajvery University

Page 40: Cancer chemotherapy

Toxicities Common ADRS : • Severe Vomiting• Bone marrow suppression• Alopecia• Stomatitis• Myelosuppression

Hajvery University

Page 41: Cancer chemotherapy

Drug Specific ADRs :• Cardiotoxicity ( Doxorubicin)• Pulmonary fibrosis ( Bleomycin)• Bladder toxicity ( Cyclophosphamide )

Hajvery University